Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAILBLAZER-ALZ 6: Different Donanemab Dosing Regimens in Early Symptomatic Alzheimer’s Disease
2022-502268-18-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3 trial of donanemab in Alzheimer's disease (AD), Dementia, Neurodegenerative disorders (NDDs) and 1 more, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E). Started Apr 2023; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)DementiaNeurodegenerative disorders (NDDs)cognitive disorder (CD)
Beyond the preview
Go deeper on 2022-502268-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502268-18-00.